tiprankstipranks
Advertisement
Advertisement
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
PremiumThe FlyPsychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
16d ago
Compass Pathways price target raised to $17 from $16 at Morgan Stanley
Premium
The Fly
Compass Pathways price target raised to $17 from $16 at Morgan Stanley
16d ago
Compass Pathways: Buy Rating Reiterated on COMP360 Progress and TRD Commercial Potential; $23 Price Target Unchanged
Premium
Ratings
Compass Pathways: Buy Rating Reiterated on COMP360 Progress and TRD Commercial Potential; $23 Price Target Unchanged
17d ago
CMPS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCMPS Upcoming Earnings Report: What to Expect?
20d ago
EXE, IP, ESPR, CMPS, TNXP Trending With Analysts
Premium
Weekend Updates
EXE, IP, ESPR, CMPS, TNXP Trending With Analysts
22d ago
Psychedelic: Jefferies initiates Compass Pathways with a Buy rating
Premium
The Fly
Psychedelic: Jefferies initiates Compass Pathways with a Buy rating
23d ago
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
PremiumThe FlyOppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
1M ago
Compass Pathways announces FDA granted NDA rolling review request
Premium
The Fly
Compass Pathways announces FDA granted NDA rolling review request
1M ago
Compass Pathways initiated with a Buy at B. Riley
Premium
The Fly
Compass Pathways initiated with a Buy at B. Riley
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100